# Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

> **NCT02003209** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 315 (actual)

## Conditions studied

- HER2-Positive Breast Carcinoma
- Hormone Receptor-Positive Breast Carcinoma
- Stage IB Breast Cancer AJCC v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7

## Interventions

- **DRUG:** Aromatase Inhibition Therapy
- **DRUG:** Carboplatin
- **OTHER:** Cytology Specimen Collection Procedure
- **DRUG:** Docetaxel
- **DRUG:** Goserelin Acetate
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pertuzumab
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Therapeutic Conventional Surgery
- **BIOLOGICAL:** Trastuzumab
- **RADIATION:** Whole Breast Irradiation

## Key facts

- **NCT ID:** NCT02003209
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-18
- **Primary completion:** 2016-10-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2025-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02003209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02003209, "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02003209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*